Margenza (margetuximab) Disease Interactions
There are 2 disease interactions with Margenza (margetuximab):
HER2 inhibitors (Includes Margenza) CHF
Moderate Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure, Hypertension, Myocardial Infarction, Arrhythmias, History - Myocardial Infarction, Post MI Syndrome
Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity. Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF. Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions. Evaluate cardiac function before, during, and upon completion of treatment. Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further. It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.
HER2 inhibitors (Includes Margenza) thrombocytopenia
Moderate Potential Hazard, Moderate plausibility. Applies to: Thrombocytopenia
Thrombocytopenia has been reported with the use of agents that block HER2 activity. Monitor platelet counts prior to initiation of therapy and prior to each dose. If appropriate modify the dose according to clinical guidelines. Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.
Margenza (margetuximab) drug interactions
There are 6 drug interactions with Margenza (margetuximab)
Margenza (margetuximab) alcohol/food interactions
There is 1 alcohol/food interaction with Margenza (margetuximab)
More about Margenza (margetuximab)
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: HER2 inhibitors
- FDA Approval History
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.